Please amend the application as shown below. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Withdrawn) A method of eliciting or inducing, in a mammal, an immune response directed to a micro-organism said method comprising administering to said mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositol glycan domain of a GPI but which molecule is substantially incapable of inducing an immune response directed to a lipidic domain of GPI.

2. (Withdrawn) A method according to claim 1 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

3. (Withdrawn) A method according to claim 2 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or derivative or equivalent thereof.

4. (Withdrawn) A method according to claim 2, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

5. (Withdrawn) A method according to claim 4 wherein said parasite is *Plasmodium*.

6. (Withdrawn) A method according to claim 5 wherein said *Plasmodium* is *Plasmodium falciparum*.

7. (Withdrawn) A method according to claim 6 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

8. (Withdrawn) A method according to claim 7 wherein said GPI inositol glycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-

Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

9. (Withdrawn) A method according to claim 7 wherein said GPI inositol glycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

10. (Withdrawn) A method according to claim 7 wherein said GPI inositolglycan domain comprises a structure selected from:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

11. (Withdrawn) A method of therapeutically or prophylactically treating a mammal for a micro-organism infection said method comprising administering to said

mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositolglycan domain of a GPI, but substantially incapable of inducing an immune response directed to the lipid domain of a GPI, for a time and under conditions sufficient for said immune response to reduce, inhibit or otherwise alleviate any one or more symptoms associated with infection of said mammal by said micro-organism.

12. (Withdrawn) A method according to claim 11 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipid domain to induce or elicit an immune response directed to a GPI lipidic domain.

13. (Withdrawn) A method according to claim 12 wherein said micro-organism infection is a parasite infection.

14. (Withdrawn) A method according to claim 13 wherein said parasite is *Plasmodium*.

15. (Withdrawn) A method according to claim 14 wherein said *Plasmodium* is *Plasmodium falciparum*.

16. (Withdrawn) A method according to claim 13 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

17. (Withdrawn) A method according to claim 16 wherein said parasite is *Plasmodium*.

18. (Withdrawn) A method according to claim 17 wherein a said *Plasmodium* is *Plasmodium falciparum*.

19. (Withdrawn) A method according to claim 18 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

20. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

21. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises the structure

X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

22. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises a structure selected from:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is

inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

23. (Withdrawn) A method for the treatment and/or prophylaxis of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositolglycan domain of a GPI, but substantially incapable of inducing an immune response directed to the lipid domain of a GPI, for a time and under conditions sufficient for said immune response to reduce, inhibit or otherwise alleviate any one or more symptoms associated with said micro-organism infections.

24. (Withdrawn) A method according to claim 23 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipid domain to induce or elicit an immune response directed to a GPI lipidic domain.

25. (Withdrawn) A method according to claim 24 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or derivative or equivalent thereof.

26. (Withdrawn) A method according to claim 24 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

27. (Withdrawn) A method according to claim 26 wherein said parasite is *Plasmodium*.

28. (Withdrawn) A method according to claim 27 wherein said *Plasmodium* is *Plasmodium falciparum*.

29. (Withdrawn) A method according to claim 28 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

30. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

31. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

32. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages

which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

33. (Withdrawn) A method according to claim 24, wherein said disease condition is malaria.

34. (Withdrawn) Use of a composition comprising a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of GPI in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a mammalian disease condition characterised by infection with said micro-organism.

35. (Withdrawn) A method according to claim 34 wherein said composition comprises a *Plasmodium* GPI inositolglycan domain or derivative or equivalent thereof which inositolglycan domain comprises insufficient lipidic domain of a *Plasmodium* GPI to elicit or induce an immune response directed to a GPI lipidic domain.

36. (Withdrawn) A composition capable of inducing an immune response directed to a micro-organism said composition comprising a molecule capable of inducing an immune response against a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response to a lipidic domain of a GPI.

37. (Withdrawn) A composition according to claim 36 wherein said molecule comprises a modified GPI molecule or derivative or equivalent thereof which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

38. (Currently amended) A ~~vaccine~~ composition comprising ~~as the active component a molecule capable of~~ modified GPI molecule or derivative or equivalent thereof which induces ~~inducing~~ an immune response directed to a micro-organism GPI inositolglycan domain but is ~~substantially~~ incapable of inducing an immune response directed to a lipidic domain of ~~a~~ said GPI~~, together with one or more pharmaceutically acceptable carriers and/or diluents~~.

39. (Cancelled) A vaccine composition according to claim 38 wherein said molecule comprises a modified GPI molecule or derivative or equivalent thereof which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

40. (Withdrawn) A pharmaceutical composition comprising a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of a GPI together with one or more pharmaceutically acceptable carriers and/or diluents.

41. (Withdrawn) A pharmaceutical composition according to claim 40 wherein said molecule comprises a modified GPI molecule or derivative or equivalent thereof which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

42. (Withdrawn) A composition according to claim 37 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

43. (Withdrawn) A composition according to claim 37 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

44. (Withdrawn) A composition according to claim 43 wherein said parasite is *Plasmodium*.

45. (Withdrawn) A composition according to claim 41 wherein said *Plasmodium* is *P.falciparum*.

46. (Withdrawn) A composition according to claim 42 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

47. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-

Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

48. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

49. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

50. (Withdrawn) An antibody directed to a GPI inositolglycan domain but which antibody is substantially incapable of interacting with the lipidic domain of a GPI.

51. (Withdrawn) A pharmaceutical composition comprising an antibody directed to a GPI inositolglycan domain, but which antibody is substantially incapable of interacting with a GPI lipidic domain, together with one or more pharmaceutically acceptable carriers and/or diluents.

52. (Withdrawn) A method of inhibiting, halting or delaying the onset or progression of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an antibody as claimed in claim 50.

53. (Cancelled) Use of an antibody according to claim 50 or 51 in the manufacture of a medicament for inhibiting, halting or delaying the onset or progression of a disease condition characterised by the infection of a mammal by a micro-organism.

54. (New) A composition according to claim 38, wherein said modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipid domain.

55. (New) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (New) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (New) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (New) A composition according to claim 57, wherein said Plasmodium is P. falciparum.

59. (New) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα 1 ,2)-Manα 1 ,2Manα 1 ,6Manα 1 ,4G1cN-myo-inositol phosphoglycerol

or a derivative or equivalent thereof.

60. (New) A composition according to claim 54 or 58, wherein said GPI inositoiglycan domain comprises the structure

X1 — X2 — X3 X4 — ethanolamine-phosphate-(Manαl,2)-

Manαl,2Manαl ,6Manαl,4GIcN-myo-inositol phosphoglycerol

wherein X1, X2, X3 and X4 are any4 amino acids, or derivative or equivalent of said GPI inositoiglycan domain.

61. (New) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[Mα 2]Mα2 Mα 6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mc~2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2] [EtN-P]Mα2 Mct6 Mα4Gu6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mo~2]{G]Mα2 Mα6 Mα4G

EtN-P-{Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mx2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mx4Gα6Ino

Mcx2 Mα6 Mα4Gu6Ino

Mα2 {Mα2]Mα6 Mα4Gα6Ino

Mci2 [Mα2][G]Mci6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][GJMα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mu6 M

EtN-P-[Mct2] [EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mcz6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2]{EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2] [G]Mα2 M

EtN-P-[Mu2][XJMcx2 M

EtN-P-[Mα2] [EtN-P]Mi2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is marmose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, mo is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.